Pues hostie

[Pues hostie @HostiePues]

@Biohazard3737 Wouldn’t you say that they’re many more examples of ideas from which your skepticism saved you? Being curious and open minded is key, but a matching skeptic trait is needed to survive out there.

[Pues hostie @HostiePues]

@WassimLaroussi3 @JoanLaportaFCB @Deco20oficial @COPE https://t.co/h7NFIR1sE9
Aquí se te ve por detrás de Laporta @WassimLaroussi3 😂

[Pues hostie @HostiePues]

@WassimLaroussi3 Indeed. But as a Spanish and Madrid fan I would’ve preferred a 5-4 win for Spain with 4 overhead Ronaldo goals

[Pues hostie @HostiePues]

@DueDoctor @adamfeuerstein 😱

[Pues hostie @HostiePues]

@WassimLaroussi3 @seedy19tron I see. Several regulatory expert colleagues I’ve asked are confident on a clean label on those numbers, but of course only time and FDA will tell.

[Pues hostie @HostiePues]

@WassimLaroussi3 @seedy19tron I’d assume prescribers would like to skip the need to enumerate the scary black box warning items from Rinvoq and rather prescribe a clean label drug with better efficacy?

[Pues hostie @HostiePues]

@Andre_AGTC @Craigster771 I agree. Hard to see inhibitors reaching biologic-like efficacy, but only clinical data will tell.
Gilead’s in licenced STAT6 degraders from LEO Pharma look highly competitive according to the patent literature.

[Pues hostie @HostiePues]

@a_a_free @Sanctuary_Bio @DmitryKovalchuk Hermanos Pollo in Madrid

[Pues hostie @HostiePues]

@ResearchPulse1 They said "severe obesity", which by their own definition is BMI > 30. But agree, will likely put the bar higher for the pilot.

[Pues hostie @HostiePues]

@seedy19tron No clin immunosuppression signal $ABVX ?

PS: Dismissed as per AESIs clinical reports though but just for reference

[Pues hostie @HostiePues]

@Banana_Oncology @SharkAlertsBio Is that conflicting data?

https://t.co/i1Kre50DaN

[Pues hostie @HostiePues]

Looking forward to seeing what turtleneck sweater shows @A_May_MD tomorrow at @BiotechTV to explain why $ABVX is down 20% after breathtaking data @bradloncar

[Pues hostie @HostiePues]

@semodough Druggability questions aside, how will a IL-4Ra inhibitor differentiate from the current wave of STAT6 inhibitors / degraders?
I still remember the day $VTYX announced they had started an IL-4Ra small molecule inhibitor program.

[Pues hostie @HostiePues]

@seedy19tron Where is the slide that refers to maket’s reaction to good data?

[Pues hostie @HostiePues]

@WassimLaroussi3 @mickeychiku @A_May_MD of patients that might benefit from the safer topical delivery. A few of my past dermatologists colleagues are really into this (kind of the past/current biologics-in-a-pill, now pill-as-topical ;-)) 2/2

[Pues hostie @HostiePues]

@WassimLaroussi3 @mickeychiku @A_May_MD For specific cases, topicals are making a come back (if they ever left). Kind of tissue specific delivery as long as systemic exposure is not the main driver of efficacy, so formulating potent, "new" MoA drugs as topicals is an effective way of perhaps reaching a segmentation 1/2

[Pues hostie @HostiePues]

@jfais20 QD etavopivat vs BID mitapivat likely to weigh in patience convenience and adherence

[Pues hostie @HostiePues]

@A_May_MD If you were to show this to the average person, I’m pretty sure their first reaction would be to think they’re looking at a before-and-after hair transplant advertisement